Post-treatment parenthood in Hodgkin's lymphoma survivors

被引:47
作者
Kiserud, C. E. [1 ]
Fossa, A.
Holte, H.
Fossa, S. D.
机构
[1] Norwegian Radium Hosp, Rikshosp, Dept Clin Canc Res, Unit Long Term Outcome, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Rikshosp, Canc Clin, N-0310 Oslo, Norway
[3] Univ Oslo, Oslo, Norway
关键词
Hodgkin's lymphoma; chemotherapy; radiotherapy; post-treatment parenthood;
D O I
10.1038/sj.bjc.6603711
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Attempted and achieved post-treatment parenthood, with or without use of assisted reproduction techniques (ARTs), was assessed in Hodgkin's lymphoma survivors treated from 1971-1998, aged below 50 (females) or 65 (males) at diagnosis, aged 18 to 75 at survey. Four treatment groups were constructed: radiotherapy only, low-, medium- and high gonadotoxic chemotherapy (with or without radiotherapy in the three chemotherapy groups). Using Kaplan-Meier estimates, log-rank tests and Cox regression analyses, factors influencing post-treatment parenthood were investigated, with birth of the first child after treatment as the end point. Fortyfive per cent (120/269) of males and 50% (91/184) of females reported attempted post-treatment parenthood. Of these, 76 (63%) males and 68 (75%) females had a child without use of ARTs. In addition 10 males and one female achieved post-treatment parenthood with use of ARTs. Treatment group was significantly associated with post-treatment parenthood, with highest probabilities after radiotherapy only and low gonadotoxic chemotherapy. In univariate analyses, age at diagnosis was a significant factor related to post-treatment parenthood in females.
引用
收藏
页码:1442 / 1449
页数:8
相关论文
共 35 条
[1]  
Aass N, 1988, Prog Clin Biol Res, V269, P481
[2]  
Abrahamsen AF, 1996, ANN ONCOL, V7, P145
[3]   Hodgkin's disease in a national and hospital population: Trends over 20 years [J].
Abrahamsen, AF ;
Egeland, T ;
Hansen, S ;
Langholm, R ;
Holte, H ;
Kvaloy, S .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (14) :2380-2383
[4]   PREGNANCY OUTCOME IN PATIENTS TREATED FOR HODGKINS-DISEASE [J].
AISNER, J ;
WIERNIK, PH ;
PEARL, P .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :507-512
[5]  
[Anonymous], PRINCIPLES PRACTICE
[6]  
ANSELMO AP, 1990, HAEMATOLOGICA, V75, P155
[7]   Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma [J].
Aurlien, E ;
Holte, H ;
Pharo, A ;
Kvaloy, S ;
Jakobsen, E ;
Smeland, EB ;
Kvalheim, G .
BONE MARROW TRANSPLANTATION, 1998, 21 (09) :873-878
[8]   Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: A report from the German Hodgkin's lymphoma study group [J].
Behringer, K ;
Breuer, K ;
Reineke, T ;
May, M ;
Nogova, L ;
Klimm, B ;
Schmitz, T ;
Wildt, L ;
Diehl, V ;
Engert, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7555-7564
[9]   CD34+ cell enrichment depletes atypical CD30+ cells from PBPC grafts in patients with HD [J].
Blystad, AK ;
Torlakovic, E ;
Holte, H ;
Kvaloy, S ;
Lenschow, E ;
Kvalheim, G .
CYTOTHERAPY, 2001, 3 (04) :295-305
[10]   High-dose therapy in patients with Hodgkin's disease:: the use of selected CD34+ cells is as safe as unmanipulated peripheral blood progenitor cells [J].
Blystad, AK ;
Holte, H ;
Kvaloy, S ;
Smeland, E ;
Delabie, J ;
Kvalheim, G .
BONE MARROW TRANSPLANTATION, 2001, 28 (09) :849-857